American Association for Cancer Research shared a post on LinkedIn:
“When patients with high-grade cervical precancers received a therapeutic HPV vaccine, half experienced clinical regression and 94% experienced lesion shrinkage, with most reductions evident within a month of vaccination, according to a study published in the AACR Journals Clinical Cancer Research. Learn more.”
